T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

Blood

Volumn 128, Issue 13, 2016, Pages 1688-1700

  Ali, Syed Abbas ^a   Shi, Victoria ^a   Maric, Irina ^b   Wang, Michael ^c   Stroncek, David F ^b   Rose, Jeremy J ^a   Brudno, Jennifer N ^a   Stetler Stevenson, Maryalice ^d   Feldman, Steven A ^a   Hansen, Brenna G ^a   Fellowes, Vicki S ^a   Hakim, Frances T ^a   Gress, Ronald E ^a   Kochenderfer, James N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; B CELL MATURATION ANTIGEN; BILIRUBIN; BORTEZOMIB; C REACTIVE PROTEIN; CARDIAC TROPONIN; CARFILZOMIB; CHIMERIC ANTIGEN RECEPTOR; CREATINE KINASE; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FIBRINOGEN; FLUDARABINE; HYDROCORTISONE; IMMUNOGLOBULIN; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; NORADRENALIN; SYNDECAN 1; TOCILIZUMAB; TROPONIN; UNCLASSIFIED DRUG; CYTOKINE; HYBRID PROTEIN; PARAPROTEIN; TNFRSF17 PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALOSIS; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIAL FIBRILLATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT; BILIRUBIN BLOOD LEVEL; BONE MARROW; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CATHETER INFECTION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CYTOPENIA; DELIRIUM; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DYSPNEA; EPISTAXIS; FEBRILE NEUTROPENIA; FEVER; FLOW CYTOMETRY; FOLLOW UP; HEADACHE; HUMAN; HYPERMAGNESEMIA; HYPERNATREMIA; HYPERTENSION; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOCYTE; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; NEUTROPHIL COUNT; PANCYTOPENIA; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PLASMA CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUS TACHYCARDIA; STOMACH DISTENSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; BLOOD; CASE REPORT; CLINICAL TRIAL; IMMUNOLOGY; LEUKOPENIA; METABOLISM; PATHOLOGY; PROCEDURES; REMISSION; TUMOR VOLUME;

B-CELL MATURATION ANTIGEN; BONE MARROW; CYTOKINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKOPENIA; MULTIPLE MYELOMA; MYELOMA PROTEINS; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; T-LYMPHOCYTES; THROMBOCYTOPENIA; TUMOR BURDEN;

EID: 84983221034     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-04-711903     Document Type: Article

References (46)

1. Runcie KD, Mark TM. Novel induction regimens in multiple myeloma. Curr Hematol Malig Rep. 2015; 10(4):388-394.
2. Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28(3):525-542.
3. Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Treatment options for relapsed and refractory multiple myeloma. Blood. 2015;125(20): 3085-3099.
4. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013; 10(5):267-276.
5. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388-398.
6. Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol. 2012;24(5):633-639.
7. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107-126.
8. Jena B, Moyes JS, Huls H, Cooper LJN. Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep. 2014;9(1):50-56.
9. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. [see comment] Nat Med. 2003;9(3):279-286.
10. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus- B-lineage leukemia effect. Blood. 2003;101(4): 1637-1644.
11. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
12. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048-2060.
13. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti- CD19 chimeric antigen receptor. J Immunother. 2009;32(7):689-702.
14. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720.
15. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
16. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16): 1507-1517.
17. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 doseescalation trial. Lancet. 2015;385(9967):517-528.
18. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
19. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549.
20. Cruz CRY, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virusspecific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965-2973.
21. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25):4129-4139.
22. Ghorashian S, Pule M, Amrolia P. CD19 chimeric antigen receptor T cell therapy for haematological malignancies. Br J Haematol. 2015;169(4): 463-478.
23. Brudno JN, Somerville RPT, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112-1121.
24. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2): 188-195.
25. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
26. Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol. 2013;31(11):999-1008.
27. Laâbi Y, Gras MP, Carbonnel F, et al. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J. 1992;11(11):3897-3904.
28. Laabi Y, Gras MP, Brouet JC, Berger R, Larsen CJ, Tsapis A. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 1994;22(7):1147-1154.
29. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18(5):263-275.
30. Ng LG, Sutherland APR, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173(2):807-817.
31. Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103(2):689-694.
32. Bellucci R, Alyea EP, Chiaretti S, et al. Graftversus- tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005;105(10):3945-3950.
33. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116(19):3875-3886.
34. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD81 T cells. J Exp Med. 2005;202(7):907-912.
35. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;155(4):1063-1074.
36. Durie BGM, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
37. Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158(6):727-738.
38. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754): 708-712.
39. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486-499.
40. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD81 T cells. Blood. 2003;101(7): 2711-2720.
41. Focosi D, Bestagno M, Burrone O, Petrini M. CD571 T lymphocytes and functional immune deficiency. J Leukoc Biol. 2010;87(1):107-116.
42. Kraut EH, Crowley JJ, Grever MR, et al. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. Invest New Drugs. 1990;8(2): 199-200.
43. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8): 914-921.
44. Garfall AL, Maus MV, Hwang WT, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015; 373(11):1040-1047.
45. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30z artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620-2630.
46. Lanitis E, Poussin M, Hagemann IS, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther. 2012;20(3):633-643.